The DNA Damaging Revolution: PARP Inhibitors and Beyond
- PMID: 31099635
- DOI: 10.1200/EDBK_238473
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Abstract
Cancer-specific DNA repair defects are abundant in malignant tissue and present an opportunity to capitalize on these aberrations for therapeutic benefit. Early preclinical data demonstrated the concept of synthetic lethality between BRCA genetic defects and pharmacologic PARP inhibition, suggesting that there may be monotherapy activity with this class of agents and supporting the early trial testing of this molecularly driven approach. Although the first foray into the clinic for PARP inhibitors was in combination with DNA-damaging cytotoxic agents, clinical development was limited by the more-than-additive toxicity, in particular dose-limiting myelosuppression. As more tolerable single agents, PARP inhibitors are now approved for the treatment of ovarian cancer in different settings and BRCA-mutant breast cancers. Beyond PARP inhibitors, there is now a large armamentarium of potent and relatively selective inhibitors in clinical trial testing against key targets involved in the DNA damage response (DDR), including ATR, ATM, CHK1/2, WEE1, and DNA-PK. These agents are being developed for patients with molecularly selected tumors and in rational combinations with other molecularly targeted agents and immune checkpoint inhibitors. We detail the clinical progress made in the development of PARP inhibitors, review rational combinations, and discuss the development of emerging inhibitors against novel DDR targets, including DNA repair proteins, DNA damage signaling, and DNA metabolism.
Similar articles
-
Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.Curr Treat Options Oncol. 2020 Jun 29;21(8):62. doi: 10.1007/s11864-020-00763-7. Curr Treat Options Oncol. 2020. PMID: 32601814 Free PMC article. Review.
-
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.Cancer. 2018 Jun 15;124(12):2498-2506. doi: 10.1002/cncr.31307. Epub 2018 Apr 16. Cancer. 2018. PMID: 29660759 Free PMC article. Review.
-
Targeting DNA repair and replication stress in the treatment of ovarian cancer.Int J Clin Oncol. 2017 Aug;22(4):619-628. doi: 10.1007/s10147-017-1145-7. Epub 2017 Jun 22. Int J Clin Oncol. 2017. PMID: 28643177 Review.
-
DNA damage response as a therapeutic target in gynecological cancers.Curr Opin Oncol. 2016 Sep;28(5):404-11. doi: 10.1097/CCO.0000000000000320. Curr Opin Oncol. 2016. PMID: 27455135
-
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.Cancer Discov. 2017 Jan;7(1):20-37. doi: 10.1158/2159-8290.CD-16-0860. Epub 2016 Dec 21. Cancer Discov. 2017. PMID: 28003236 Free PMC article. Review.
Cited by
-
Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis.Cancers (Basel). 2020 Oct 18;12(10):3026. doi: 10.3390/cancers12103026. Cancers (Basel). 2020. PMID: 33081005 Free PMC article.
-
Bi-directional regulation of AIMP2 and its splice variant on PARP-1-dependent neuronal cell death; Therapeutic implication for Parkinson's disease.Acta Neuropathol Commun. 2024 Jan 3;12(1):5. doi: 10.1186/s40478-023-01697-5. Acta Neuropathol Commun. 2024. PMID: 38172953 Free PMC article.
-
The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas.J Immunother Precis Oncol. 2020 Nov 12;3(4):157-164. doi: 10.36401/JIPO-20-20. eCollection 2020 Nov. J Immunother Precis Oncol. 2020. PMID: 35665372 Free PMC article. Review.
-
Focus on DNA Glycosylases-A Set of Tightly Regulated Enzymes with a High Potential as Anticancer Drug Targets.Int J Mol Sci. 2020 Dec 3;21(23):9226. doi: 10.3390/ijms21239226. Int J Mol Sci. 2020. PMID: 33287345 Free PMC article. Review.
-
CCAR2 functions downstream of the Shieldin complex to promote double-strand break end-joining.Proc Natl Acad Sci U S A. 2022 Dec 6;119(49):e2214935119. doi: 10.1073/pnas.2214935119. Epub 2022 Nov 29. Proc Natl Acad Sci U S A. 2022. PMID: 36442094 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
